Clinical Trial Detail

NCT ID NCT03495713
Title RADVAX FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

Hodgkin's lymphoma

Therapies

Nivolumab

Age Groups: adult senior

No variant requirements are available.